Challenges and opportunities of metabolomics

The metabolome is a data‐rich source of information concerning all the low‐molecular‐weight metabolites in a biofluid, which can indicate early biological changes to the host due to perturbations in metabolic pathways. Major changes can be seen after minor stimuli, which make it a valuable target for analysis. Due to the diverse and sensitive nature of the metabolome, studies must be designed in a manner to maintain consistency, reduce variation between subjects, and optimize information recovery. Technological advancements in experimental design, mouse models and instrumentation have aided in this effort. Metabolomics has the ultimate potential to be valuable in a clinical setting where it could be used for early diagnosis of a disease and as a predictor of treatment response and survival. During drug treatment, the metabolic status of an individual could be monitored and used to indicate possible toxic effects. Metabolomics therefore has great potential for improving diagnosis, treatment and aftercare of disease.

[1]  E. Want,et al.  Systemic gut microbial modulation of bile acid metabolism in host tissue compartments , 2010, Proceedings of the National Academy of Sciences.

[2]  J. Idle,et al.  Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. , 2007, Molecular endocrinology.

[3]  John N Weinstein,et al.  UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. , 2008, Analytical chemistry.

[4]  J. Idle,et al.  Radiation Metabolomics. 3. Biomarker Discovery in the Urine of Gamma-Irradiated Rats Using a Simplified Metabolomics Protocol of Gas Chromatography-Mass Spectrometry Combined with Random Forests Machine Learning Algorithm , 2009, Radiation research.

[5]  Caroline H. Johnson,et al.  Radiation Metabolomics. 4. UPLC-ESI-QTOFMS-Based Metabolomics for Urinary Biomarker Discovery in Gamma-Irradiated Rats , 2011, Radiation research.

[6]  J. Idle,et al.  A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4 , 2008, Drug Metabolism and Disposition.

[7]  R. Knight,et al.  The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice , 2009, Science Translational Medicine.

[8]  J. Idle,et al.  A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. , 2006, Chemical research in toxicology.

[9]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[10]  Gary Siuzdak,et al.  Nanostructure-initiator mass spectrometry metabolite analysis and imaging. , 2011, Analytical chemistry.

[11]  Gary Siuzdak,et al.  A nanostructure-initiator mass spectrometry-based enzyme activity assay , 2008, Proceedings of the National Academy of Sciences.

[12]  W. R. Wikoff,et al.  Metabolomics identifies perturbations in human disorders of propionate metabolism. , 2007, Clinical chemistry.

[13]  Donald G Robertson,et al.  Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  A. Fornace,et al.  UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model. , 2011, Journal of proteome research.

[15]  Matthias Heinemann,et al.  Single cell metabolomics. , 2011, Current opinion in biotechnology.

[16]  P. Britz‐McKibbin,et al.  Metabolomic studies of radiation‐induced apoptosis of human leukocytes by capillary electrophoresis‐mass spectrometry and flow cytometry: Adaptive cellular responses to ionizing radiation , 2010, Electrophoresis.

[17]  D. Wishart Advances in metabolite identification. , 2011, Bioanalysis.

[18]  D. Gauguier,et al.  Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.

[19]  D. Guo,et al.  Pregnane X receptor-mediated induction of Cyp3a by black cohosh , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  R. T. Williams,et al.  The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. , 1971, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  Philip J. Marriott,et al.  Principles and applications of comprehensive two-dimensional gas chromatography , 2002 .

[22]  John C Lindon,et al.  Pharmacometabonomics as an effector for personalized medicine. , 2011, Pharmacogenomics.

[23]  D. Schaid,et al.  Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics‐Informed Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[24]  David J Greenblatt,et al.  The effect of grapefruit juice on drug disposition , 2011, Expert opinion on drug metabolism & toxicology.

[25]  Albert J Fornace,et al.  Radiation Metabolomics. 1. Identification of Minimally Invasive Urine Biomarkers for Gamma-Radiation Exposure in Mice , 2008, Radiation research.

[26]  J. Idle,et al.  Identification of Novel Toxicity-associated Metabolites by Metabolomics and Mass Isotopomer Analysis of Acetaminophen Metabolism in Wild-type and Cyp2e1-null Mice* , 2008, Journal of Biological Chemistry.

[27]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[28]  Silas G. Villas-Boas,et al.  Analytical methods from the perspective of method standardization , 2007 .

[29]  Qian Yang,et al.  Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. , 2010, Journal of proteome research.

[30]  S. Z. Imam,et al.  Medicinal importance of grapefruit juice and its interaction with various drugs , 2007, Nutrition journal.

[31]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[32]  J. Nicholson,et al.  Global systems biology and personalized healthcare solutions. , 2006, Discover medicine.

[33]  J. Caldwell,et al.  The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol. Studies in neomycin-pretreated and germ-free mice. , 1988, Biochemical pharmacology.

[34]  A. Kassis,et al.  Putative molecular signatures for the imaging of prostate cancer , 2010, Expert review of molecular diagnostics.

[35]  Oscar Yanes,et al.  Nanostructure initiator mass spectrometry: tissue imaging and direct biofluid analysis. , 2009, Analytical chemistry.

[36]  Junefredo V. Apon,et al.  Clathrate nanostructures for mass spectrometry , 2007, Nature.

[37]  F. Wright,et al.  Use of Pharmaco‐Metabonomics for Early Prediction of Acetaminophen‐Induced Hepatotoxicity in Humans , 2010, Clinical pharmacology and therapeutics.

[38]  T. Fan,et al.  Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM) , 2009, Molecular Cancer.

[39]  Caroline H. Johnson,et al.  Xenobiotic metabolomics: major impact on the metabolome. , 2012, Annual review of pharmacology and toxicology.

[40]  J. Idle,et al.  A metabolomic perspective of melatonin metabolism in the mouse. , 2008, Endocrinology.

[41]  John C Lindon,et al.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.

[42]  Leo L. Cheng,et al.  Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. , 2005, Cancer research.

[43]  Oliver Fiehn,et al.  Plasma Metabolomic Profiles Reflective of Glucose Homeostasis in Non-Diabetic and Type 2 Diabetic Obese African-American Women , 2010, PloS one.

[44]  Nigel W. Hardy,et al.  Summary recommendations for standardization and reporting of metabolic analyses , 2005, Nature Biotechnology.

[45]  E. Want,et al.  HILIC-UPLC-MS for exploratory urinary metabolic profiling in toxicological studies. , 2011, Analytical chemistry.

[46]  A. Darzi,et al.  Metabolic phenotyping for monitoring surgical patients , 2011, The Lancet.

[47]  Nigel W. Hardy,et al.  A proposed framework for the description of plant metabolomics experiments and their results , 2004, Nature Biotechnology.

[48]  J. Idle,et al.  Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity , 2009, Drug Metabolism and Disposition.

[49]  A. Fornace,et al.  Radiation Metabolomics. 2. Dose- and Time-Dependent Urinary Excretion of Deaminated Purines and Pyrimidines after Sublethal Gamma-Radiation Exposure in Mice , 2009, Radiation research.

[50]  M. Rantalainen,et al.  Top-down systems biology modeling of host metabotype-microbiome associations in obese rodents. , 2009, Journal of proteome research.

[51]  I. Wilson,et al.  An NMR‐based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse , 2000, FEBS letters.

[52]  J. Ward,et al.  THE CYP 2 E 1-HUMANIZED TRANSGENIC MOUSE : ROLE OF CYP 2 E 1 IN ACETAMINOPHEN HEPATOTOXICITY , 2004 .

[53]  J. Idle,et al.  The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. , 2007, Biochemical pharmacology.

[54]  J. Idle,et al.  A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. , 2007, Chemical research in toxicology.

[55]  Y. Pommier,et al.  Urinary Metabolite Profiling Reveals CYP1A2-Mediated Metabolism of NSC686288 (Aminoflavone) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[56]  I. Wilson,et al.  The role of gut microbiota in drug response. , 2009, Current pharmaceutical design.

[57]  R. L. Brown,et al.  Development of a database of gas chromatographic retention properties of organic compounds. , 2007, Journal of chromatography. A.

[58]  J C Lindon,et al.  Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. , 1998, Journal of pharmaceutical and biomedical analysis.

[59]  John C Lindon,et al.  Kinetic and J-resolved statistical total correlation NMR spectroscopy approaches to structural information recovery in complex reacting mixtures: application to acyl glucuronide intramolecular transacylation reactions. , 2008, Analytical chemistry.

[60]  Weiqun Li,et al.  Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation , 2010, Drug Metabolism and Disposition.

[61]  I. Wilson,et al.  High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. , 2005, Journal of proteome research.

[62]  J. Idle,et al.  Fenofibrate Metabolism in the Cynomolgus Monkey using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics , 2009, Drug Metabolism and Disposition.

[63]  Julian L Griffin,et al.  Proton NMR analysis of plasma is a weak predictor of coronary artery disease , 2006, Nature Medicine.

[64]  Ian D Wilson,et al.  Hydrophilic interaction and reversed-phase ultra-performance liquid chromatography TOF-MS for metabonomic analysis of Zucker rat urine. , 2008, Journal of separation science.

[65]  Ai-Ming Yu,et al.  THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY , 2005, Drug Metabolism and Disposition.

[66]  Yves Gibon,et al.  GMD@CSB.DB: the Golm Metabolome Database , 2005, Bioinform..

[67]  John O. Prior,et al.  Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Idle,et al.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. , 2010, Biochemical pharmacology.

[69]  S. Bartz,et al.  Attenuation of Slc27a5 gene expression followed by LC-MS measurement of bile acid reconjugation using metabolomics and a stable isotope tracer strategy. , 2011, Journal of proteome research.

[70]  Elaine Holmes,et al.  A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model , 2007, Molecular systems biology.

[71]  Kazuki Saito,et al.  Potential of metabolomics as a functional genomics tool. , 2004, Trends in plant science.

[72]  Warwick B Dunn,et al.  Current trends and future requirements for the mass spectrometric investigation of microbial, mammalian and plant metabolomes , 2008, Physical biology.

[73]  D. Nebert,et al.  Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. , 2005, Chemical research in toxicology.

[74]  A. Lane,et al.  Metabolic profiling identifies lung tumor responsiveness to erlotinib. , 2009, Experimental and molecular pathology.

[75]  P. Arn,et al.  Newborn screening: current status. , 2007, Health affairs.

[76]  O. Pelkonen,et al.  CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[77]  O. Fiehn,et al.  FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. , 2009, Analytical chemistry.

[78]  Matthew R. Redinbo,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[79]  F. Gonzalez,et al.  Metabolomics identifies novel Hnf1alpha-dependent physiological pathways in vivo. , 2010, Molecular endocrinology.

[80]  T. Kodama,et al.  Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[81]  Gabriel S. Eichler,et al.  Metabolomics Reveals Attenuation of the SLC6A20 Kidney Transporter in Nonhuman Primate and Mouse Models of Type 2 Diabetes Mellitus* , 2011, The Journal of Biological Chemistry.

[82]  P. Britz‐McKibbin,et al.  Comprehensive plasma thiol redox status determination for metabolomics. , 2011, Journal of proteome research.

[83]  J. Idle,et al.  A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. , 2011, Biochemical pharmacology.

[84]  J. Griffin,et al.  Cryogenic probe 13C NMR spectroscopy of urine for metabonomic studies. , 2002, Analytical chemistry.

[85]  A. Lane,et al.  Stable isotope-resolved metabolomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. , 2011, Omics : a journal of integrative biology.

[86]  Ruth E Ley,et al.  Obesity and the human microbiome , 2010, Current opinion in gastroenterology.

[87]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.